Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow ZTS
Zoetis Inc. (ZTS) Revenue
Zoetis Inc.'s revenue for fiscal 2025 was $9.5B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $9.5B. Over the past ten years it has ranged from $4.8B (fiscal 2015) to $9.5B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 10 consecutive fiscal years. Zoetis Inc. ranks 6th of 75 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $9.5B | 2.28% |
| FY2024 | $9.3B | 8.33% |
| FY2023 | $8.5B | 5.74% |
| FY2022 | $8.1B | 3.91% |
| FY2021 | $7.8B | 16.49% |
| FY2020 | $6.7B | 6.63% |
| FY2019 | $6.3B | 7.47% |
| FY2018 | $5.8B | 9.76% |
| FY2017 | $5.3B | 8.57% |
| FY2016 | $4.9B | 2.58% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $2.5B | 9.11% |
| Mar 2026 | $2.3B | (5.55%) |
| Dec 2025 | $2.4B | (0.21%) |
| Sep 2025 | $2.4B | (2.99%) |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $30.0B |
| HLN Haleon PLC Sponsored ADR compare | $18.1B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $17.3B |
| VTRS Viatris Inc. compare | $14.7B |
| ZTS Zoetis Inc. | $9.5B |
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.4B |
| NBIX Neurocrine Biosciences, Inc. compare | $3.4B |
| UTHR United Therapeutics Corporation compare | $3.2B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ZTS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement